UBS has maintained its buy rating on SBI Life, with a share price target of ₹1,940, implying a 13.3% upside from the current market price (CMP). The company has launched new products, with a special focus on pure protection. According to management, the impact of these new launches is expected to become visible from Q3 due to delayed launches in Q2.
Persistency, excluding the 37th month, saw improvement across various cohorts, further bolstering the outlook.
Currently, SBI Life’s stock is trading at ₹1,711.70.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Please consult with a qualified financial advisor before making any investment decisions.
